A MEC nanoprobe, its preparation method and application

By developing a GSH-responsive dual-modal imaging nanoprobe Mn-TCPP-MOF-Era-CD133mab, combined with MRI T1 imaging and fluorescence imaging, the ferroptosis resistance pathway in pancreatic cancer was blocked, solving the assessment challenge in existing technologies and realizing visualization of pancreatic cancer ferroptosis resistance and precision in treatment strategies.

CN121550424BActive Publication Date: 2026-05-26THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIV +2
2 Cites 0 Cited by

Patent Information

Application Number
CN202610076296.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2026-01-21
Publication Date
2026-05-26
Estimated Expiration
2046-01-21

AI Technical Summary

Technical Problem

Existing technologies are insufficient to effectively assess ferroptosis resistance mechanisms in pancreatic cancer, especially due to the lack of in vivo visualization assessment methods, which affects the selection of treatment options, and chemotherapy and immunotherapy are prone to developing drug resistance.

Method used

A GSH-responsive dual-modal imaging nanoprobe, Mn-TCPP-MOF-Era-CD133mab, was developed. The metabolism and ferroptosis resistance of the nanoprobe were reflected by MRI T1 imaging and fluorescence imaging. The ferroptosis resistance pathway was blocked by a combination therapy strategy. The Mn-MOF nanoprobe was loaded with the Xc-system inhibitor Erastin and CD133mab, combined with the TGFβR1 inhibitor Repsox, to induce ferroptosis in tumor cells.

Benefits of technology

This study achieved dual-channel blockade of ferroptosis resistance in pancreatic cancer. By visually assessing the metabolism and ferroptosis resistance of the nanoprobes in vivo, it deepened the understanding of the regulatory mechanism of ferroptosis in pancreatic cancer and provided a theoretical basis for targeting the tumor microenvironment to reverse ferroptosis resistance.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

This invention discloses a MEC nanoprobe, its preparation method, and its applications. The MEC nanoprobe is composed of Mn... 3+ The sample was prepared using TCPP, Erastin, and CD133mab, with CD133mab coupled to the surface. The preparation method involved adding Mn... 3+ Mn-TCPP-MOF was synthesized by stirring TCPP in an N,N-dimethylformamide solution containing acetic acid; Erastin was then added and stirred at room temperature, followed by centrifugation, washing, and redispersing in deionized water; the amide bonds were then activated via EDC / NHS and coupled to CD133mAb to obtain MEC nanoprobes. The combined application of this MEC nanoprobe with a TGFβ1R inhibitor can block both the classical ferroptosis resistance pathway and CAF-related pathways, achieving dual-channel blockade of ferroptosis resistance in pancreatic cancer. Furthermore, dual-modal imaging enables semi-quantitative in vivo visualization assessment of ferroptosis resistance, demonstrating promising clinical application prospects.
Need to check novelty before this filing date? Find Prior Art